| Identification | More | [Name]
(R)-Tomoxetine | [CAS]
83015-26-3 | [Synonyms]
n-methyl-3-(2-methylphenoxy)benzenepropanamine
(r)-tomoxetine
Tomoxetine
TomoxetineHcl
N-Methyl--(2-methylphenoxy)benzenepropanamine
N-Methyl-3-(2-methylphenoxy)-3-phenylpropylamine
(R)-N-Methyl-3-phenyl-3-(2-methylphenoxy)-1-propanamine
Methyl[(R)-3-phenyl-3-(2-methylphenoxy)propyl]amine | [EINECS(EC#)]
617-427-9 | [Molecular Formula]
C17H21NO | [MDL Number]
MFCD00865352 | [Molecular Weight]
255.35 | [MOL File]
83015-26-3.mol |
| Hazard Information | Back Directory | [Uses]
(R)-Tomoxetine is a compound active at novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases.
| [Definition]
(R)-Tomoxetine is a secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.
| [Brand name]
Strattera
(Lilly). | [in vivo]
Atomoxetine (Tomoxetine) (0.3-3 mg/kg; i.p.; 0-4 hours; male Sprague-Dawley rats) increases extracellular norepinephrine and dopamine by 3-fold and increases Fos expression in the rat prefrontal cortex[1].
Atomoxetine (Tomoxetine) (0.1-5 mg/kg; i.p. and p.o; for 14 days; spontaneously hypertensive rat) can improve behaviors associated with ADHD in rats[3]. | Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 0.3, 1 and 3 mg/kg | | Administration: | Intraperitoneal injection; for 4 hours | | Result: | Increased the number of cells expressing Fos-like immunoreactivity in PFC 3.7-fold and increased extracellular norepinephrine and dopamine by 3-fold. |
| Animal Model: | Spontaneously hypertensive rat (SHR)[3] | | Dosage: | 0.1, 0.3, 1.25 and 5.0 mg/kg | | Administration: | Intraperitoneal injection and oral administration; for 14 days | | Result: | Had non-impact on the measurement of motor activity. |
|
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|